Drug profile · INN
aminosalicylic acid
PASER
aminosalicylic acid (PASER) is a dihydrofolate reductase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — aminosalicylic acid
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
aminosalicylic acid (PASER) is a dihydrofolate reductase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Dihydrofolate reductase inhibitor
Primary target: Dihydrofolate reductase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is aminosalicylic acid?
aminosalicylic acid (PASER) is a dihydrofolate reductase inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for aminosalicylic acid?
PASER is a marketed brand name for aminosalicylic acid. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of aminosalicylic acid?
aminosalicylic acid has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.